Vimarsana
Biggest News Aggregation in the World

Page 2 - Mapi Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mapi Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mapi Research Today - Breaking & Trending Today

University of Birmingham, U.K. announces 'all language capability' for tool to expedite Long COVID research - Vimarsana News

University of Birmingham, U.K. announces 'all language capability' for tool to expedite Long COVID research

BIRMINGHAM, England, Dec. 8, 2022 /PRNewswire/ -- A validated Symptom Burden Questionnaire that will help medical researchers unravel the complexities of Long COVID and develop or test new treatments

Keep eCOA Off the Critical Path of Clinical Trial Startup, Upcoming Webinar Hosted by Xtalks - Vimarsana News

Keep eCOA Off the Critical Path of Clinical Trial Startup, Upcoming Webinar Hosted by Xtalks

Toronto, ON (PRWEB) September 21, 2022 -- In today’s patient-driven and competitive drug development landscape, healthcare organizations and related clinical

Source: prweb.com
Cureus | Health-Related Quality of Life Among HIV-Infected Children and Its Association With Socio-Demographic, Clinical and Nutritional Variables: A Comparative Approach - Vimarsana News

Cureus | Health-Related Quality of Life Among HIV-Infected Children and Its Association With Socio-Demographic, Clinical and Nutritional Variables: A Comparative Approach

Background: The human immunodeficiency virus (HIV) infection and its treatment impact the child’s life as well as that of their caregivers. As therapeutic advances are made in the field, improved survival has shifted the focus from morbidity and mortality to quality of life. This study aims to compare the health-related quality of life (HRQoL) of children living with HIV in comparison with an HIV-negative control group and determine its relationship with socio-demographic, clinical, and nutritional variables. Method: This was a multi-center cross-sectional comparative study involving 274 pa...

Source: cureus.com
Dupilumab Shows Benefits in Larger EoE Cohort - Vimarsana News

Dupilumab Shows Benefits in Larger EoE Cohort

In a phase 3 trial of adults and adolescents with hard-to-treat eosinophilic esophagitis, 6 months of weekly dupilumab sent 59% of participants into disease remission.